[go: up one dir, main page]

ES2190083T3 - Diazepinoindoles inhibidores de fosfodiesterasa 4'. - Google Patents

Diazepinoindoles inhibidores de fosfodiesterasa 4'.

Info

Publication number
ES2190083T3
ES2190083T3 ES98925598T ES98925598T ES2190083T3 ES 2190083 T3 ES2190083 T3 ES 2190083T3 ES 98925598 T ES98925598 T ES 98925598T ES 98925598 T ES98925598 T ES 98925598T ES 2190083 T3 ES2190083 T3 ES 2190083T3
Authority
ES
Spain
Prior art keywords
formula
compounds
phosphodiesterase
diazepinoindoles
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98925598T
Other languages
English (en)
Inventor
Yves Pascal
Catherine Burnouf
Bernard Gaudilliere
Henry Jacobelli
Alain Calvet
Adrian Payne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Holding France SCA
Original Assignee
Pfizer Holding France SCA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Holding France SCA filed Critical Pfizer Holding France SCA
Application granted granted Critical
Publication of ES2190083T3 publication Critical patent/ES2190083T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos que inhiben la fosfodiesterasa 4 y que corresponden a la fórmula (I). La invención se refiere también a procedimientos de utilización de los compuestos de la fórmula (I), en la prevención o el tratamiento del asma, determatitis atópicas, poliartritis reumatoide, colopatías funcionales, hipertensión arterial pulmonar, ataques hepáticos, rarefacción ósea, choques sépticas o esclerosis múltiple. La invención se refiere también a composiciones farmacéuticas que contienen los compuestos de la fórmula (I).
ES98925598T 1997-04-30 1998-04-30 Diazepinoindoles inhibidores de fosfodiesterasa 4'. Expired - Lifetime ES2190083T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9705422A FR2762841B1 (fr) 1997-04-30 1997-04-30 Diazepino-indolones inhibitrices de phosphodiesterases iv

Publications (1)

Publication Number Publication Date
ES2190083T3 true ES2190083T3 (es) 2003-07-16

Family

ID=9506517

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98925598T Expired - Lifetime ES2190083T3 (es) 1997-04-30 1998-04-30 Diazepinoindoles inhibidores de fosfodiesterasa 4'.

Country Status (17)

Country Link
US (1) US6239130B1 (es)
EP (1) EP0980374B1 (es)
JP (1) JP2001522367A (es)
KR (1) KR20010020386A (es)
AT (1) ATE232534T1 (es)
AU (1) AU729495B2 (es)
BR (1) BR9809429A (es)
CA (1) CA2278217A1 (es)
DE (1) DE69811360T2 (es)
DK (1) DK0980374T3 (es)
ES (1) ES2190083T3 (es)
FR (1) FR2762841B1 (es)
HR (1) HRP980231B1 (es)
MX (1) MXPA99006979A (es)
NZ (1) NZ337589A (es)
WO (1) WO1998049169A1 (es)
ZA (1) ZA983704B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2795731B1 (fr) * 1999-07-02 2001-09-07 Warner Lambert Co PROCEDE DE PREPARATION DE [1,4] DIAZEPINO [6,7,1-hi] INDOL-4-ONES SUBSTITUEES
JP2003525288A (ja) * 2000-03-03 2003-08-26 ファイザー・プロダクツ・インク 抗炎症剤／鎮痛剤としてのピラゾールエーテル誘導体
EP1161949A1 (en) 2000-06-09 2001-12-12 Warner-Lambert Company Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
MXPA03010672A (es) 2001-05-23 2004-03-02 Tanabe Seiyaku Co Composicion para el tratamiento regenerativo de enfermedades del cartilago.
US20040146561A1 (en) * 2001-05-23 2004-07-29 Naoki Sakurai Compositions for promoting healing of bone fracture
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
US20090042951A1 (en) * 2004-02-20 2009-02-12 Robert Danziger Blood Pressure Reduction in Salt-Sensitive Hypertension
AU2005234783A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
NZ561746A (en) * 2005-04-19 2011-09-30 Nycomed Gmbh Roflumilast for the treatment of pulmonary hypertension
CN101547922B (zh) * 2006-10-04 2012-06-20 辉瑞产品公司 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物
US20080254029A1 (en) * 2007-04-11 2008-10-16 Alcon Research, Ltd. Use of an Inhibitor of TNFa Plus an Antihistamine to Treat Allergic Rhinitis and Allergic Conjunctivitis
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
EP2170306A1 (en) * 2007-06-26 2010-04-07 Lexicon Pharmaceuticals, Inc. Methods of treating serotonin-mediated diseases and disorders
KR20120091037A (ko) * 2009-10-01 2012-08-17 알콘 리서치, 리미티드 올로파타딘 조성물 및 그의 용도
MX2021007938A (es) 2018-12-28 2022-01-24 Regeneron Pharma Tratamiento de trastornos respiratorios con inhibidores de la araquidonato 15-lipooxigenasa (alox15).

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725719B1 (fr) * 1994-10-14 1996-12-06 Jouveinal Inst Rech Diazepino-indoles inhibiteurs de phosphodiesterases iv

Also Published As

Publication number Publication date
EP0980374B1 (en) 2003-02-12
DE69811360D1 (de) 2003-03-20
EP0980374A1 (en) 2000-02-23
ATE232534T1 (de) 2003-02-15
AU729495B2 (en) 2001-02-01
DK0980374T3 (da) 2003-05-05
HRP980231B1 (en) 2002-06-30
US6239130B1 (en) 2001-05-29
HRP980231A2 (en) 2000-04-30
AU7765298A (en) 1998-11-24
BR9809429A (pt) 2000-06-13
FR2762841A1 (fr) 1998-11-06
NZ337589A (en) 2000-10-27
CA2278217A1 (en) 1998-11-05
ZA983704B (en) 1999-10-25
JP2001522367A (ja) 2001-11-13
MXPA99006979A (es) 2005-04-19
KR20010020386A (ko) 2001-03-15
DE69811360T2 (de) 2003-10-09
FR2762841B1 (fr) 1999-07-02
WO1998049169A1 (en) 1998-11-05

Similar Documents

Publication Publication Date Title
ES2190083T3 (es) Diazepinoindoles inhibidores de fosfodiesterasa 4'.
PL314605A1 (en) Isoxazolin compounds as anti-inflammatory agents
ATE187447T1 (de) 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel
ATE450515T1 (de) Anilinopyrimidinderivate als ikk?inhibitoren, und hiermit in zusammenhang stehende zusammensetzungen und verfahren
MX9606546A (es) Compuestos inhibidores de la enzima conversiva de interleukina-1 beta.
AU2721402A (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
WO2003041643A3 (en) Hsp90-inhibiting zearalanol compounds and methods of producing and using same
DE69824037D1 (de) Beta-alanin-derivate als zell-adhäsions-inhibitoren
BG104138A (en) 2-aminopyridines containing substituents with condensed rings as nos inhibitors
ES2195419T3 (es) Inhibidores bencenosulfonamida de pde-iv y su uso terapeutico.
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
AP2000001992A0 (en) Succinamide inhibitors of inteleukin-1B converting enzyme.
BG104292A (en) Methods and compositions for the treatment of rheumatoid arthritis
YU18399A (sh) Postupak alkilacije zaštićenih sulfonamida
PT1294729E (pt) 2-aminoalquil-tieno[2,3-d]pirimidinas
MX9805015A (es) INHIBIDORES DE LA ENZIMA QUE CONVIERTE LA INTERLEUCINA-1 beta.